deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03829254

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma

Sponsor: NuCana plc

Conditions Advanced Cancer Lymphoma Melanoma Solid Tumor
Interventions NUC-7738 Pembrolizumab
Updated 15 times since 2019 Last updated: Jan 8, 2026 Started: Jun 17, 2019 Primary completion: Aug 31, 2026 Completion: Aug 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Cancer and Lymphoma and is currently actively recruiting participants. NuCana plc leads this study, which shows 15 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Jan 2023 · 11 months · monthly snapshot~Jan 2023 – ~Jul 2023 · 6 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~May 2024 · 6 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Recruiting PHASE1/PHASE2

  3. Dec 2024 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 10 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Nov 2023 — May 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jul 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  7. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE1

  8. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  9. Aug 2019 — Jan 2021 [monthly]

    Recruiting PHASE1

  10. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NuCana plc
Data source: NuCana plc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations